Short Bowel Syndrome Market Size is Anticipated to Reach US$728.3 Million to US$3.67 Billion by 2031 | Exclusive Report By TMR

The global short bowel syndrome (SBS) market, valued at US$728.3 million in 2020, is poised for remarkable growth over the forecast period. It is anticipated to expand at a robust compound annual growth rate (CAGR) of 15.9% from 2021 to 2031, reaching approximately US$3,672.4 million (or US$3.67 billion) by the end of 2031. This exceptional growth reflects the increasing recognition of SBS as a significant gastrointestinal condition, coupled with advancements in therapeutic options and rising patient needs. As healthcare systems address this rare but impactful disorder, the SBS market is set to quintuple in value, highlighting its critical role in medical care through 2031.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346

Understanding Short Bowel Syndrome and Its Market

Short bowel syndrome is a malabsorptive condition resulting from the surgical removal of a significant portion of the small intestine, often due to Crohn's disease, cancer, or trauma. It leads to nutrient deficiencies, diarrhea, and dependency on parenteral nutrition (PN). The market includes therapies like glucagon-like peptide-2 (GLP-2) analogs (e.g., teduglutide), growth hormones, and anti-diarrheal agents, alongside supportive care. The 2020 valuation of US$728.3 million underscores its niche but growing presence, with the projected rise to US$3.67 billion by 2031 emphasizing its rapid expansion amid unmet needs.

The 15.9% CAGR signals a highly dynamic growth phase, driven by innovation and disease burden. SBS's complexity and rarity fuel a robust therapeutic pipeline, ensuring strong market momentum.

Key Drivers of Market Growth

Several factors are propelling the SBS market toward its US$3.67 billion valuation by 2031. First, the increasing prevalence of underlying conditions is a key driver. Rising cases of inflammatory bowel diseases (e.g., Crohn's), intestinal cancers, and surgical interventions are expanding the SBS patient pool. Improved survival rates post-surgery also mean more individuals require long-term management, aligning with the market's 15.9% CAGR.

Second, advancements in treatment options are accelerating growth. The approval of teduglutide (Gattex/Revestive), a GLP-2 analog, has revolutionized SBS care by reducing PN dependence and enhancing intestinal adaptation. Ongoing research into next-generation therapies-such as longer-acting GLP-2 analogs or oral nutrient enhancers-further drives the market toward US$3.67 billion, offering hope for better quality of life.

Third, growing healthcare investments and awareness are boosting demand. Orphan drug designations and incentives from agencies like the FDA encourage R&D for rare diseases like SBS. Patient advocacy and physician education are increasing diagnosis rates, supporting the market's trajectory as specialized care gains traction globally.

Leading Players:

Takeda Pharmaceutical Company Limited
Merck KGaA
Zealand Pharma A/S
OxThera
VectivBio AG
9 Meters Biopharma, Inc.
Nutrinia Ltd.
Hanmi Pharm.Co., Ltd.
Pharmascience, Inc.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346

Market Segmentation and Regional Insights

The market segments by product type, distribution channel, and geography. GLP-2 analogs dominate, reflecting their efficacy and market penetration, followed by growth hormones and supportive therapies. Hospital pharmacies lead distribution due to the need for specialized administration, with retail and online channels growing for supportive care products. End-users include hospitals, specialty clinics, and home care settings.

Regionally, North America held a significant share of the US$728.3 million valuation in 2020, driven by advanced healthcare systems, high adoption of teduglutide, and strong reimbursement in the United States. Europe followed, with robust markets in Germany and the UK, supported by rare disease initiatives. The Asia-Pacific region, however, is expected to see the fastest growth through 2031, fueled by improving healthcare infrastructure, rising surgical procedures, and awareness in China and India.

Challenges and Opportunities

The market faces challenges. High treatment costs-teduglutide therapy can exceed tens of thousands annually-limit accessibility, while long-term PN reliance poses infection risks and complications. Limited awareness in developing regions delays diagnosis, and a small patient population restricts large-scale trials. Regulatory hurdles for new drugs also slow progress.

These challenges, however, present opportunities. Companies developing cost-effective alternatives or oral therapies could broaden access, supporting the push to US$3.67 billion. Innovations in PN safety, like infection-resistant catheters, and expanded screening in emerging markets offer growth potential. Partnerships with healthcare providers to integrate therapies with nutritional support could exceed projections, enhancing patient outcomes.

The Road to 2031

By 2031, the global SBS market is expected to reach US$3.67 billion, reflecting 11 years of exceptional growth at a 15.9% CAGR from US$728.3 million in 2020. This trajectory is driven by disease prevalence, therapeutic breakthroughs, and global health efforts. As the forecast concludes, the market's momentum suggests continued expansion, with potential for personalized treatments to shape future advances.

In conclusion, the SBS market demonstrates extraordinary growth from 2021 to 2031. Rising from US$728.3 million to US$3.67 billion, it addresses a rare but severe condition with transformative impact. Stakeholders-from pharma innovators to clinicians-play a vital role in this success, ensuring effective solutions reach patients worldwide through 2031 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Pharma 4.0 Market: https://www.pharmiweb.com/press-release/2025-03-18/pharma-40-market-size-will-estimated-to-grow-at-a-cagr-of-177-by-2035-driven-by-digital-transformation-in-drug-manufacturing-exclusive-report-by

Dialysis Equipment Market: https://www.pharmiweb.com/press-release/2025-03-18/dialysis-equipment-market-poised-to-surpass-us-252-bn-by-2035-amidst-rising-ckd-cases-and-technological-advancements-tmr-insights

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.